UPDATE 1-Novo Holdings set to win EU nod for $16.5 bln Catalent deal, source says

Reuters11-23

(Adds the European Commission declines comment, Novo and Catalent did not immediately respond to request for comments, details)

By Foo Yun Chee and Maggie Fick

BRUSSELS/LONDON, Nov 22 (Reuters) - Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug maker Catalent

, a person with direct knowledge of the matter said on Friday, clearing a key hurdle.

Another source said Catalent is preparing senior management for the deal to go through.

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk , whose profit from blockbuster weight-loss drug Wegovy has made it Europe's most valuable company by market value.

The deal would help Novo Nordisk boost output of Wegovy, a once-weekly injection.

The European Commission, which acts as the EU competition watchdog and has set a Dec. 6 deadline for its decision, declined to comment.

Novo Holdings, Novo Nordisk and Catalent did not immediately respond to requests for comment.

In May, the companies said they had received a second request from the U.S. Federal Trade Commission $(FTC.UK)$ for more information on the deal. However, there has been no update from the U.S. antitrust agency since then.

(Reporting by Foo Yun Chee in Brussels and Maggie Fick in London; Editing by Louise Heavens)

((foo.yunchee@thomsonreuters.com; +32 2 585 2866; Reuters Messaging: foo.yunchee.thomsonreuters.com@reuters.net))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485294996?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-23 01:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485294996","market":"us","top_or_hot":-1,"title":"UPDATE 1-Novo Holdings set to win EU nod for $16.5 bln Catalent deal, source says","media":"Reuters","content":"<html><body><p>(Adds the European Commission declines comment, Novo and <a href=\"https://laohu8.com/S/CTLT\">Catalent</a> did not immediately respond to request for comments, details)</p><p>   By Foo Yun Chee and Maggie Fick</p><p>      BRUSSELS/LONDON, Nov 22 (Reuters) - Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug maker Catalent</p><p> , a person with direct knowledge of the matter said on Friday, clearing a key hurdle.</p><p>       Another source said Catalent is preparing senior management for the deal to go through.</p><p>   Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk   , whose profit from blockbuster weight-loss drug Wegovy has made it Europe's most valuable company by market value.</p><p>   The deal would help Novo Nordisk boost output of Wegovy, a once-weekly injection.</p><p>   The European Commission, which acts as the EU competition watchdog and has set a Dec. 6 deadline for its decision, declined to comment.</p><p>       Novo Holdings, Novo Nordisk and Catalent did not immediately respond to requests for comment.</p><p>       In May, the companies said they had received a second request from the U.S. Federal Trade Commission <a href=\"https://laohu8.com/S/FTC.UK\">$(FTC.UK)$</a> for more information on the deal. However, there has been no update from the U.S. antitrust agency since then.</p><p> (Reporting by Foo Yun Chee in Brussels and Maggie Fick in London; Editing by Louise Heavens)</p><p>((foo.yunchee@thomsonreuters.com; +32 2 585 2866; Reuters Messaging: foo.yunchee.thomsonreuters.com@reuters.net))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-Novo Holdings set to win EU nod for $16.5 bln Catalent deal, source says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-Novo Holdings set to win EU nod for $16.5 bln Catalent deal, source says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-23 01:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Adds the European Commission declines comment, Novo and Catalent did not immediately respond to request for comments, details)   By Foo Yun Chee and Maggie Fick      BRUSSELS/LONDON, Nov 22 (Reuters)...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4156","symbol_name":"煤与消费用燃料","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2485294996","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485294996","pubTimestamp":1732297808,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"(Adds the European Commission declines comment, Novo and Catalent did not immediately respond to request for comments, details)   By Foo Yun Chee and Maggie Fick      BRUSSELS/LONDON, Nov 22 (Reuters)","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4156":"煤与消费用燃料","BK4585":"ETF&股票定投概念","CTLT":"Catalent","BK4530":"医药外包概念","BK4588":"碎股","BK4007":"制药","FTC":"First Trust Large Cap Growth Opp"},"translate_title":"更新1-消息人士称，Novo Holdings将赢得欧盟对Catalent 165亿美元交易的认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTLT":1,"FTC":1},"content_text":"(Adds the European Commission declines comment, Novo and Catalent did not immediately respond to request for comments, details)   By Foo Yun Chee and Maggie Fick      BRUSSELS/LONDON, Nov 22 (Reuters) - Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug maker Catalent , a person with direct knowledge of the matter said on Friday, clearing a key hurdle.       Another source said Catalent is preparing senior management for the deal to go through.   Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk   , whose profit from blockbuster weight-loss drug Wegovy has made it Europe's most valuable company by market value.   The deal would help Novo Nordisk boost output of Wegovy, a once-weekly injection.   The European Commission, which acts as the EU competition watchdog and has set a Dec. 6 deadline for its decision, declined to comment.       Novo Holdings, Novo Nordisk and Catalent did not immediately respond to requests for comment.       In May, the companies said they had received a second request from the U.S. Federal Trade Commission $(FTC.UK)$ for more information on the deal. However, there has been no update from the U.S. antitrust agency since then. (Reporting by Foo Yun Chee in Brussels and Maggie Fick in London; Editing by Louise Heavens)((foo.yunchee@thomsonreuters.com; +32 2 585 2866; Reuters Messaging: foo.yunchee.thomsonreuters.com@reuters.net))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485294996"}